Novartis Investigative Site

Terrebonne, Quebec J6X 4P7

0 studies enrolling now · 8 studies all time

What they study most

Acute Myocardial Infarction, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Cardiovascular Events, Heart Failure With Preserved Ejection Fraction (HFpEF), Primary Prevention of Atherosclerotic Cardiovascular Disease

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People — Stopped early